Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of...
Patent
1996-03-05
1999-07-20
Campell, Bruce R.
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
424 9321, 435455, 4353201, 435 691, 514 44, 536 231, 536 241, C12N 1500
Patent
active
059255650
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
The present invention relates to a DNA fragment isolated from a retrotransposon and comprising an internal ribosome entry site (IRES). More especially, it relates to expression vectors containing this DNA fragment, and in particular to polycistronic vectors permitting the efficient and stable expression of several genes of interest under the control of the same promoter. The present invention finds advantageous application in the field of gene therapy vectors.
The feasibility of gene therapy applied to man no longer needs to be demonstrated, and this relates to many therapeutic applications such as genetic disorders, infectious diseases and cancer. Many documents of the prior art describe the means of implementing gene therapy, in particular by the use of viral vectors. Generally speaking, the vectors are obtained by deletion of at least a portion of the viral genes which are replaced by the genes of therapeutic interest. Such vectors may be propagated in a complementation line which supplies in trans the deleted viral functions, to generate a viral vector particle which is defective for replication but capable of infecting a host cell. To date, retroviral vectors are among the ones most often used, but vectors originating from adenoviruses, adeno-associated viruses, poxviruses and herpesviruses may also be mentioned. This type of vector, their organization and their mode of infection are widely described in the literature available to a person skilled in the art.
It can be advantageous to have at one's disposal more efficacious gene therapy vectors capable, in particular, of producing several proteins of interest efficiently. However, the presence of several promoters within the same vector very often manifests itself in a reduction or even a loss of expression over time. This is due to a well-known phenomenon of interference between promoter sequences. In this context, the publication of International Application WO93/03143 proposes a solution to this problem which consists in employing an internal ribosome entry site (IRES). It describes a dicistonic retroviral vector for the expression of two genes of interest placed under the control of the same promoter. The presence of a picornavirus IRES site between these genes permits the production of the expression product originating from the second gene of interest by internal initiation of the translation of the dicistronic MRNA.
Normally, the entry of ribosomes into messenger RNA takes place via the cap located at the 5' end of all eukaryotic mRNAs. However, there are exceptions to this universal rule. The absence of a cap in some viral mRNAs suggests the existence of alternative structures permitting the entry of ribosomes at an internal site of these RNAs. To date, a number of these structures, designated IRES on account of their function, have been identified in the 5' noncoding region of uncapped viral mRNAs, such as that, in particular, of picornaviruses such as the poliomyelitis virus (Pelletier et al., 1988, Mol. Cell. Biol., 8, 1103-1112) and the EMCV virus (encephalo-myocarditis virus (Jang et al., J. Virol., 1988, 62, 2636-2643).
SUMMARY OF THE INVENTION
A new internal ribosome entry site has now been found in type VL30 murine retrotransposons, and this site has been shown to improve the translation of the coding sequences placed after it.
The genome of eukaryotic cells comprises a number of mobile genetic elements called transposons, which have the capacity to move from one site of the genome to another chosen at random. At the present time, their function and biological significance is not known. Some of them, the retrotransposons, appear to be related to retroviral proviruses by their organization and their mode of transposition (via an intermediate RNA, reverse transcription and integration in the cell genome). The different murine retrotransposons identified to date include the VL30 elements. The murine genome comprises from 150 to 200 copies of this. They are approximately 6 kb in length and possess direct rep
REFERENCES:
patent: 5354674 (1994-10-01), Hodgson
C. Bordignon et al, "Gene Therapy in Peripheral Blood Lymphocytes and Bone Marrow for ADA.sup.- Immunodeficient Patients", Science (1995) 270:470-475.
R. Michael Blaese et al., "T Lymphocyte-Directed Gene Therapy for ADA.sup.- SCID: Initial Trial Results After 4 Years", Science (1995) 270:475-480.
G. Nabel et al, "Immune Response in Human Melanoma After Transfer of an Allogeneic Class I Major Histocompatibility Complex Gene with DNA-Liposome Complexes", Proc. Natl. Acad. Sci USA, (1996) 93:15388-15393.
J. Pelletier et al. "Cap-Independent Translation of Poliovirus mRNA is Conferred by Sequence Elements within the 5' Noncoding Region", Molecular and Cellular Biology, (1988) 8:1103-1112, No. 3.
"A small and efficient dimerization/packaging signal of rat VL30 RNA and its use in murine leukemia virus-VL30-derived vectors for gene transfer", Journal of Virology, vol. 68, No. 2, pp. 661-667, Torrent, C. et al.
"Analytical study of rat retrotransponson VL30 RNA dimerization in vitro and packaging in murine leukemia virus", Journal of Molecular Biology 240 (5). 1994. 434-444. Torrent, C. et al.
"Nucleotide sequence of mouse virus-like (VL30) retrotransposon BVL-1", Nucleic Acids Research, vol. 18, No. 3, Oxford GB, p. 673, Hodgson, C. et al.
"Complete nucleotide sequence of a mouse VL30 retro-element", Molecular and Cellular Biology, vol. 8, No. 8, Washington US, pp. 2989-2998, Adams S. et al.
"New generation of safe, efficient retroviral vectors and packaging cell lines for application in gene therapy trials", Keystone Symposium on Gene Therapy and Molecular Medicine, Steamboat Springs, Colorado, USA, Mar. 26-Apr. 1, 1995. Journal of Cellular Biochemistry Supplement 0 (21A). 1995. 408, Homann, H. et al.
"Expression of VL30 vectors in primary cell types which are targets for gene therapy", Keystone Symposium on Gene Therapy and Molecular Medicine, Steamboat Springs, Colorado, USA, Mar. 26-Apr. 1, 1995. Journal of Cellular Biochemistry Supplement 0 (21A). 1995. 408, Hodgson, C. et al.
Kappel et al (1992). Current Opinion: Biotechnology 3, 548-553.
Orkin and Motulsky, (1995). Report and Recommendations of the Panel to Assess the NIH Investment: Research on Gene Therapy.
Mulligan, R. (1993). Science 260, 926-932.
Jolly, D. (1994). Cancer Gene Therapy 1 , 51-64.
Adams, S et al (1988). Molecular and Cellular Biology 8, 2989-98.
Morgan, R. et al (1992). Nucleic Acids Res. 20, 1293-1299.
Lewin, R. (1987). Science 237, 1570.
Reeck et al (1987). Cell 50, 667.
Cook, R. et al (1991). Biotechnology 9, 748-51.
Chakraborty, A et al (1993). FASEB Journal 7, 971-7.
Makris, A. et al (1993). J. Virol. 67, 1286-1291.
Torrent, C. et al (1992). Bone Marrow Transpl. 9 (Supp. 1), 143-147.
Adam, M et al (1991). J. Virol. 65, 4985-4990.
Ghattas, I. et al (1991). Mol. Cell. Biol. 11, 5848-5859.
Berlioz et al (1995). Journal of Virology 69, 2214-22.
Berlioz Clarisse
Darlix Jean-Luc
Jacquemoud Sandrine
Torrent Christophe
Campell Bruce R.
Institut National de la Sante et de la Recherche Medicale
Nguyen Dave Trong
LandOfFree
Internal ribosome entry site, vector containing it and therapeut does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Internal ribosome entry site, vector containing it and therapeut, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Internal ribosome entry site, vector containing it and therapeut will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1321556